In-vivo imaging of tumor associated urokinase-type plasminogen activator activity
- 1 January 2006
- journal article
- Published by SPIE-Intl Soc Optical Eng in Journal of Biomedical Optics
- Vol. 11 (3) , 034013-5
Abstract
The ability to image tumor associated protease in vivo has biological and clinical implications. In the present study, we describe the development and validation of a urokinase-type plasminogen activator (uPA) sensitive fluorescence imaging probe. The activation of our probe is highly specific to uPA in both enzymatic and cellular-based assays. In two distinct in-vivo tumor models (human colon adenocarcinoma HT-29 and human fibrosarcoma HT-1080), the observed fluorescence changes correlate well with tumor associated uPA activity. The signal intensities of the tumors are about three-fold higher in animals with probe injections. Our results suggest a direct detection method for uPA activity in vivo and the approach can be used for monitoring tumor growth and development.Keywords
This publication has 24 references indexed in Scilit:
- Design of Novel and Selective Inhibitors of Urokinase-type Plasminogen Activator with Improved Pharmacokinetic Properties for Use as Antimetastatic AgentsJournal of Biological Chemistry, 2004
- Inhibition of the invasion capacity of carcinoma cells by WX‐UK1, a novel synthetic inhibitor of the urokinase‐type plasminogen activator systemInternational Journal of Cancer, 2004
- Intra-arterial thrombolysis in acute ischemic stroke: a review of pharmacologic approachesExpert Review of Cardiovascular Therapy, 2004
- Design, Synthesis, and Characterization of Urokinase Plasminogen-Activator-Sensitive Near-Infrared ReporterChemistry & Biology, 2004
- Urokinase Plasminogen Activator SystemClinical Orthopaedics and Related Research, 2003
- Protease sensors for bioimagingAnalytical and Bioanalytical Chemistry, 2003
- Molecular mechanisms of glioma invasiveness: the role of proteasesNature Reviews Cancer, 2003
- The Protease Inhibitor Bikunin, a Novel Anti-Metastatic AgentBiological Chemistry, 2003
- Pooled Analysis of Prognostic Impact of Urokinase-Type Plasminogen Activator and Its Inhibitor PAI-1 in 8377 Breast Cancer PatientsJNCI: Journal of the National Cancer Institute, 2002
- Receptor‐mediated endocytosis of plasminogen activators and activator/inhibitor complexesFEBS Letters, 1994